TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

Running, not enrolling · Phase 1/Phase 2

Conditions studied: Metastatic Solid Tumor

In brief

TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2. TAC directs T-cells to the targeted antigen (CLDN 18.2), and once engaged with the target, activates them via the endogenous T cell receptor. This is an open-label, multicenter Phase ½ study that aims to establish safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-CLDN18.2.

Key facts

Study ID

NCT05862324

Run by

Triumvira Immunologics, Inc.

People needed

113

Starts

2023-08-23

Expected to finish

2027-08-01

Last updated by the study team

2025-02-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed, written informed consent obtained before any study procedures are conducted.
• Age ≥ 18 years at the time of informed consent.
• Tumor tissue samples positive for CLDN18.2 as assessed by central laboratory.
• Histologically confirmed advanced, metastatic, unresectable CLDN18.2+ solid tumors after at least 2 lines of prior therapy (Phase 1) and after at least 2 and no more than 4 prior lines of therapy (Phase 2). Subjects with PDAC may have been treated with 1 line of prior therapy.
• Subjects with incurable Claudin 18.2 expressing malignancies for which no standard-of-care targeted therapy exists may be enrolled regardless of the number of prior treatment lines.
• Specific Phase 1 tumor types include gastric, GEJ, esophageal adenocarcinoma, PDAC, colorectal cancer, cholangiocarcinoma, ovarian mucinous cancer, gallbladder cancer and NSCLC.
• Specific Phase 2 tumor types include gastric and esophageal adenocarcinoma (Group A), PDAC (Group B), and ovarian or NSCLC (Group C). Other tumor types are not eligible.
• Subjects with solid tumors with genetic alterations and mutations (e.g., BRAF, BRCA, EGFR mutations, and ALK translocation) where approved targeted therapies were available to their specific cancers must have been previously treated with such approved therapies, or refused such approved targeted therapy for their cancers, prior to enrollment, or in the opinion of the Investigator would be unlikely to tolerate or derive clinically meaningful benefit from these standard-of-care therapies.
• Measurable disease per RECIST 1.1 at time of enrollment.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at Screening.
• Life expectancy of at least 12 weeks.
• Adequate organ and bone marrow reserve function prior to leukapheresis as outlined in protocol.
• Recovery to Grade ≤ 1 or baseline for any toxicities due to previous therapy, except alopecia, anemia, thrombocytopenia, neutropenia, and neuropathy.
• If a subject received major surgery, they must have recovered from the procedure and/or any complications from the procedure prior to starting TAC01-CLDN18.2 therapy.
• Toxicity that has not recovered to Grade ≤ 1 is allowed if it meets the inclusion requirements for laboratory parameters.
• Adequate vascular access for leukapheresis as per institutional standards
• For women physiologically capable of becoming pregnant, agreement to use highly effective methods of contraception starting 28 days prior to study treatment and continue for 1 year after the last TAC01-CLDN18.2 infusion. For men who have partners physiologically capable of becoming pregnant, agreement to use an effective barrier contraceptive method and refrain from donating sperm during study treatment and for 1 year after the last TAC01-CLDN18.2 infusion.
• Subjects who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to enrollment. Note: Subjects should remain on antiviral therapy throughout study intervention and follow local guidelines for HBV antiviral therapy post completion of study intervention.
• Subjects with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at Screening. Note: Subjects must have completed curative antiviral therapy at least 4 weeks prior to enrollment.

You may not qualify if…

• Intolerant to any component of TAC01-CLDN18.2
• Prior treatment with any of the following:
• Adoptive cell transfer of any kind, including CAR T cells.
• Gene therapy
• Prior treatment with a CLDN18.2 targeted agent (Phase 2 only)
• Investigational medicinal product within 5 half-lives or 21 days prior to leukapheresis, whichever is shorter.
• Participation in or has participated in a study using an investigational device within 4 weeks prior to the first dose of study treatment.
• Receipt of a live or live-attenuated vaccine within 30 days prior to the first dose of study Intervention. Administration of killed vaccines are allowed.
• Radiation within 28 days prior to leukapheresis. Palliative radiation is allowed up to 14 days prior to leukapheresis if additional non-irradiated lesions are present.
• Chemotherapy or targeted small molecule therapy within 14 days prior to leukapheresis, or within 7 days prior to leukapheresis for erlotinib, gefitinib, afatinib, or crizotinib in NSCLC subjects.
• Colony stimulating factors, including granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoietin, and other hematopoietic cytokines, within 14 days prior to leukapheresis.
• Immunosuppressive medication within 14 days or corticosteroid treatment < 72 hours prior to leukapheresis, except for physiological replacement doses (< 12 mg/m2/24 hours of hydrocortisone or equivalent) and topical or inhaled steroids.
• History or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.
• Known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study Screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
• Active inflammatory neurological disorders (e.g., Guillain-Barre Syndrome, amyotrophic lateral sclerosis, multiple sclerosis).
• Active autoimmune disease (e.g., lupus, rheumatoid arthritis, Sjogren's syndrome) requiring systemic disease modifying agents in the past 2 years. Hormone replacement therapy (e.g., thyroxine, insulin), or physiologic corticosteroid replacement therapy (for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
• Active or uncontrolled hepatitis B or C (HCV ribonucleic acid [RNA] positive) infection or any history of or active human immunodeficiency virus (HIV) infection.
• Uncontrolled, acute, or life-threatening bacterial, viral, or fungal infection. Subjects with ongoing use of prophylactic antibiotics, antifungals, or antivirals are eligible if there is no evidence of active infection (includes COVID positive subjects).
• Class III or IV heart failure (as defined by the New York Heart Association [NYHA]), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease within 6 months prior to Screening.
• Cardiac arrhythmia not controlled by medical management.
• Clinically significant thrombotic events within 3 months prior to leukapheresis and/or inability to stop anticoagulation for at least 2 weeks prior to TAC01-CLDN18.2 infusion without compromising a subject's health (except in subjects with PDAC).
• Prior radiation therapy to the lung > 30 Gy within 6 months of the first dose of study treatment.
• History of Grade ≥ 3 drug-induced pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
• Ongoing unstable or active gastrointestinal ulcers and gastrointestinal bleeding.
• Complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent/recurrent vomiting.

Where it is running

• University of Southern California — Los Angeles, California, United States
• University of California San Diego — San Diego, California, United States
• University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Cincinnati Cancer Center — Cincinnati, Ohio, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Princess Margaret Cancer Center — Toronto, Ontario, Canada
• Centre hospitalier de l'Université de Montréal — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.